Technology Bundle ID: NCI-E-137-2016

A Triple Combination HIV Microbicide

Request More Info
Licensing Contact:
Co-Inventors: 
Barry OKeefe (NCI), Evangelia Vavamka (University of Lleida), Paul Christou (University of Lleida), Teresa Capell (University of Lleida)
Application: 
Therapeutics
Development Status: 

Discovery (Lead Identification)

Institute or Center: 
NCI

The HIV-positive population continues to rise despite a worldwide decline in the rates of infection caused by human immunodeficiency virus (HIV).  The HIV virus continues to spread due to a lack of effective vaccines and pre-exposure prophylaxis methods, even though the availability and effectiveness of antiretroviral therapy has helped reduce acquired immunodeficiency syndrome (AIDS)-related deaths. 

Researchers at the National Cancer Institute (NCI), in collaboration with researchers at the University of Lleida, developed a triple combination microbicide for the prevention of HIV and other sexually transmitted diseases. The microbicide is comprised of an endosperm, the anti-HIV monoclonal antibody 2G12, and the antiviral lectins griffithsin and cyanovirin. The researchers have generated the microbicide combination in transgenic plants as an efficient and cost-effective production method. 

Applications:
  • Effective anti-HIV microbicide with activity against other viruses as well (HSV, HCV)
Advantages:
  • Low cost, stable production method
  • Stable and long-term storage compatible rice seed

Patents

Application 62/591,569
Filed on 2017-11-28

Updated

Aug 14, 2018

Data Source: 
nci